An authoritative, structured guide detailing cellular biology, risk factors, early warning indicators, multimodal staging diagnostics, personalised treatment options, and survivorship at TLJCC.
Accurate classification and molecular profiling are the bedrock of cancer management at TLJCC. Every tumour possesses unique biological features that dictate its behaviour, progression rate, and response to specific therapies.
Breast cancer originates from epithelial cells in the ducts or lobules of the breast. Early detection through regular screening and clinical assessment significantly improves treatment efficacy and long-term outcomes.
Cancer develops when genetic alterations disrupt normal cellular controls, allowing cells to multiply unchecked, invade surrounding tissue, or potentially spread through lymphatic channels and blood vessels.
At TLJCC, diagnostic tissue specimens undergo comprehensive immunohistochemical and genomic profiling. Identifying molecular markers (such as hormone receptor status and gene mutations) ensures each patient receives therapies designed specifically for their tumour profile.
Factors may include age, genetic predispositions (such as BRCA1/BRCA2 alterations), hormonal exposures, lifestyle factors, and familial history. While some risk factors cannot be modified, early assessment and lifestyle adjustments remain vital.
Many early symptoms can be caused by benign conditions. However, new, persistent, or worsening physical changes should be reviewed promptly by an experienced clinician.
A firm, painless swelling or thickening felt in breast tissue or under the armpit that does not fluctuate with menstrual cycles.
Skin alterations such as puckering, redness, or an orange-peel texture (peau d’orange) caused by obstructed lymphatic drainage.
Unexplained retraction or flattening of the nipple, or spontaneous serous/blood-stained discharge from a single duct.
Localised discomfort or swelling in the axillary region that persists independent of hormonal fluctuations.
Unexplained change in the contour, shape, elevation, or symmetry of one breast compared to the other.
Persistent eczema-like flaking, crusting, or itching around the nipple areolar complex that fails to heal with topical cream.
Early-stage disease is frequently asymptomatic and detected via routine screening. If you discover a palpable lump, persistent skin change, or unexplained bleeding, schedule an evaluation immediately.
Accurate diagnosis at TLJCC follows an integrated, multi-step sequence combining physical examination, high-resolution diagnostic imaging, and pathology analysis to guide therapeutic planning.
Fecal occult blood test to identify microscopic occult bleeding alongside digital rectal examination.
Full endoscopic visualization of the large intestine with direct polypectomy and biopsy of suspicious lesions.
Mandatory high-resolution rectal MRI to assess mesorectal fascia margin and depth of local invasion.
Cross-sectional imaging of thorax, abdomen, and pelvis to detect hepatic or pulmonary micrometastases.
Staging describes the anatomical extent of disease to guide prognosis and treatment strategy.
| Stage | Clinical Characteristics | Diagnostic & Therapeutic Intent |
|---|---|---|
| Stage I | Tumour confined within bowel submucosa or muscularis propria (T1-T2N0M0); zero nodal spread. | Curative surgical resection alone; 5-year survival exceeds 90%. |
| Stage II | Tumour penetrates through bowel muscular wall (T3-T4N0M0) without regional lymph node involvement. | Surgical resection with selective adjuvant chemotherapy based on high-risk histological features. |
| Stage III | Any T-stage with confirmed tumour metastasis to 1 or more regional mesenteric lymph nodes. | Definitive surgery followed by adjuvant FOLFOX or CAPOX chemotherapy. |
| Stage IV | Distant metastatic disease in the liver, peritoneum, or lungs. | Systemic chemotherapy, targeted anti-EGFR / anti-VEGF biologics, and selective surgical metastasectomy. |
TLJCC combines state-of-the-art surgical oncology, precision linear accelerator radiotherapy, and targeted systemic medical oncology into a unified care plan.
No single doctor makes complex cancer decisions alone. Every case is collaboratively reviewed by a team of surgeons, radiation oncologists, medical oncologists, radiologists, and pathologists to agree on the safest, most effective personalized path forward.
Surgical Oncology
Surgical excision tailored to tumour location, from oncoplastic lumpectomy to skin-sparing mastectomy and immediate reconstruction.
Radiation Oncology
Advanced image-guided external beam radiation to eradicate microscopic residual cells while strictly protecting cardiac and pulmonary tissue.
Medical Oncology
Evidence-based cytotoxic chemotherapy administered prior to surgery to shrink tumours or post-operatively to eliminate micro-metastatic risk.
Targeted Therapy
Monoclonal antibodies and antibody-drug conjugates specifically targeting cellular receptors driving malignant breast cell growth.
Hormone Therapy
Long-term targeted therapy designed to deprive hormone receptor-positive (HR+) tumour cells of estrogen stimulation.
Supportive Care
Comprehensive physical and psychological support throughout your care trajectory, led by certified clinical breast care specialists.
Cancer care extends beyond tumour eradication. TLJCC provides comprehensive supportive therapies to manage side effects, preserve emotional wellbeing, and ensure long-term physical recovery.
Connect directly with verified specialists at TLJCC with deep clinical expertise in managing this cancer type.
Being well-informed empowers you and your loved ones to participate actively in clinical discussions and decision-making.
TLJCC provides authoritative guides across all major cancer types treated at our centre in Johor Bahru.
Our dedicated patient liaison team can guide you to the appropriate specialist clinic and assist with appointment scheduling.
